Alteogen Licenses Biologics Tech to Biogen

Alteogen Inc. has entered into an exclusive license agreement with Biogen Inc. for the development and commercialization of its Hybrozyme™-based subcutaneous biologics. This partnership allows Biogen to leverage Alteogen's innovative technology for creating advanced biologic therapies. The agreement is expected to accelerate the development of new treatments and expand the reach of these promising biologics. This collaboration highlights the growing importance of innovative drug delivery platforms in the biopharmaceutical industry and positions both companies for future growth.